StreetInsider.com News Articles

Form SCHEDULE 13D/A CVRx, Inc. Filed by: Chernett Jorey

Fri, 02 Oct 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20261002/27144155.html

CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026

Tue, 29 Sep 2026 16:30:00 -0400

MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations featuring Barostim at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026. The meeting will be held Oct. 9-12, 2026, in Phoenix.

Barostim will be featured across eight events at HFSA, including late-breaking clinical data, a rapid-fire session, posters and podium sessions. BENEFIT-HF, the landmark clinical trial initiated earlier this year evaluating Barostim in an expanded population, will also

CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026

Tue, 29 Sep 2026 16:30:00 -0400

Canaccord Reiterates Buy Rating on CVRx Inc (CVRX)

Tue, 22 Sep 2026 06:46:09 -0400

Canaccord analyst William Plovanic reiterated a Buy rating and $5.00 price target on CVRx Inc (NASDAQ: CVRX).

The analyst commented: "Today, after the close, CVRX press released that it will be appointing John Landry as its next CFO to succeed Jared Oasheim, whose resignation was previously announced. Mr. Landry will join the company on October 12, 2026, and Mr. Oasheim will transfer over responsibilities to Mr. Landry the day after the company files its 10-Q for the quarter ended September 30, 2026 Mr. Landry brings significant experience to the CFO role at CVR, including over 20 years of financial leadership in

Form 8-K CVRx, Inc. For: Sep 16

Mon, 21 Sep 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260921/27085481.html

CVRx names John Landry as its new chief financial officer

Mon, 21 Sep 2026 16:07:36 -0400

CVRx, Inc. (NASDAQ: CVRX) announced the appointment of John Landry as Chief Financial Officer, succeeding Jared Oasheim, who previously announced his resignation. According to a press release, Landry will join the Minneapolis-based medical device company on October 12, 2026, and will assume the CFO role the day after CVRx files its Form 10-Q for the quarter ending September 30, 2026. Oasheim will remain with the company during a transition period consistent with his previously disclosed transition agreement.

Landry brings more than two decades of financial leadership experience in the medical device industry. He currently serves as CFO of Nyxoah SA (Euronext

CVRx names John Landry as its new chief financial officer

Mon, 21 Sep 2026 16:07:36 -0400

Landry brings more than two decades of financial leadership experience in the medical device industry. He currently serves as CFO of Nyxoah SA (Euronext

CVRx Appoints John Landry as Chief Financial Officer

Mon, 21 Sep 2026 16:07:00 -0400

MINNEAPOLIS, Sept. 21, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that John Landry has been appointed Chief Financial Officer, succeeding Jared Oasheim, whose resignation was previously announced. Mr. Landry will join the Company on October 12, 2026, and assume the CFO role on the day after the Company files its Form 10-Q for the quarter ending September 30, 2026. Mr. Oasheim will remain with the Company for a transition period consistent with his previously disclosed

CVRx Appoints John Landry as Chief Financial Officer

Mon, 21 Sep 2026 16:07:00 -0400

CVRx Appoints John Landry as Chief Financial Officer

Mon, 21 Sep 2026 16:07:00 -0400

CVRx Appoints John Landry as Chief Financial Officer

Mon, 21 Sep 2026 16:07:00 -0400

CVRx board responds to shareholder letter on valuation concerns

Tue, 25 Aug 2026 08:04:12 -0400

CVRx, Inc. (NASDAQ: CVRX) issued a statement on Aug. 25, 2026, responding to a public letter from Jorey Chernett of Pointillist Family Office, addressed to CVRx's Board of Directors and dated Aug. 24, 2026.

In its statement, the CVRx board said it "regularly evaluates a full range of options to maximize value for all shareholders" and acknowledged an "open dialogue" with Chernett.

The company said it agrees with Chernett's characterization of its Barostim device as a "highly differentiated, validated therapy" and that CVRx's current valuation "does not fully capture the potential of the underlying business." The board added it is "confident in

CVRx board responds to shareholder letter on valuation concerns

Tue, 25 Aug 2026 08:04:12 -0400

In its statement, the CVRx board said it "regularly evaluates a full range of options to maximize value for all shareholders" and acknowledged an "open dialogue" with Chernett.

CVRx Responds to Letter from Pointillist Family Office

Tue, 25 Aug 2026 08:00:00 -0400

MINNEAPOLIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today issued the following statement in response to the public letter to CVRx’s Board of Directors from Jorey Chernett at Pointillist Family Office, dated August 24, 2026:

The Board of Directors and leadership team are committed to acting in the best interests of all CVRx shareholders and regularly evaluate a full range of options to maximize value for all shareholders. The Board values all shareholder input

CVRx Responds to Letter from Pointillist Family Office

Tue, 25 Aug 2026 08:00:00 -0400

CVRx Responds to Letter from Pointillist Family Office

Tue, 25 Aug 2026 08:00:00 -0400

CVRx Responds to Letter from Pointillist Family Office

Tue, 25 Aug 2026 08:00:00 -0400

Form SCHEDULE 13D CVRx, Inc. Filed by: Chernett Jorey

Mon, 24 Aug 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260824/26969532.html

Form SCHEDULE 13D CVRx, Inc. Filed by: Chernett Jorey

Mon, 24 Aug 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260824/26969532.html

CVRx, Inc. Investors Who Suffered Losses Should Contact Block & Leviton LLP

Mon, 24 Aug 2026 11:21:00 -0400

Boston, Massachusetts--(Newsfile Corp. - August 24, 2026) - Block & Leviton is investigating CVRx, Inc. (NASDAQ: CVRX) for potential securities law violations. Investors who have lost money in their CVRx, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/cvrx.

What is this all about?

Block & Leviton is investigating whether CVRx and certain of its executives misrepresented or failed to timely disclose material information about the company's sales execution, growth, and revenue outlook. On August 6, 2026, CVRx cut its full-year revenue guidance to $58-60 million from a prior

CVRx, Inc. Investors Who Suffered Losses Should Contact Block & Leviton LLP

Mon, 24 Aug 2026 11:21:00 -0400

What is this all about?

CVRx shareholder pushes board to pursue sale of the company

Mon, 24 Aug 2026 08:32:31 -0400

Jorey Chernett, founder of Pointillist Family Office and beneficial owner of more than 5.5% of outstanding shares of CVRx, Inc. (NASDAQ: CVRX), has delivered a letter to the CVRx board of directors urging it to launch a formal process to sell the company to a strategic acquirer.

In the letter, Chernett argues that CVRx's Barostim product would be valuable to a large medical device company and that a sale could be accretive to an acquirer within twelve months. He contends that a sale would allow CVRx shareholders to realize value that the company cannot deliver on a standalone basis.

Chernett's letter calls

CVRx shareholder pushes board to pursue sale of the company

Mon, 24 Aug 2026 08:32:31 -0400

Chernett's letter calls

CVRx shareholder pushes board to pursue sale of the company

Mon, 24 Aug 2026 08:32:31 -0400

Chernett's letter calls

CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

Mon, 24 Aug 2026 08:30:00 -0400

MINNEAPOLIS, Aug. 24, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Devoted Health has issued a Medicare Advantage coverage policy for Barostim therapy, effective July 17, 2026. Devoted Health, a national health insurance company with the eighth largest Medicare Advantage enrollment in the U.S., provides coverage to approximately 466,000 Medicare Advantage members across 29 states.

The new policy covers Barostim for patients meeting its current FDA-approved indication as well as patients enrolled in the